CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...
A U.S. regulator reportedly plans to unveil a faster approach to approving custom gene-editing treatments for rare diseases.
A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...
Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...
A lthough still in its early days, CRISPR has already been called the most powerful scientific tool of the century. Using ...
These horses might look like ordinary horses, but there is something highly unusual about their genomes. They are the first of their species to have their DNA edited using CRISPR–Cas9, a technique ...
With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...
The idea that a single-celled bacterium can defend itself against viruses in a similar way as the 1.8-trillion-cell human immune system is still “mind-blowing” for molecular biologist Joshua Modell of ...
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback